S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Urgent Warning (Ad)
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
"Prepare for Five Years of Famine" (Ad)
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
"Prepare for Five Years of Famine" (Ad)
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Urgent Warning (Ad)
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
"Prepare for Five Years of Famine" (Ad)
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
"Prepare for Five Years of Famine" (Ad)
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Urgent Warning (Ad)
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
"Prepare for Five Years of Famine" (Ad)
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
"Prepare for Five Years of Famine" (Ad)
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Urgent Warning (Ad)
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
"Prepare for Five Years of Famine" (Ad)
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
"Prepare for Five Years of Famine" (Ad)
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
NASDAQ:REPL

Replimune Group - REPL Price Target & Analyst Ratings

$19.47
+0.67 (+3.56%)
(As of 03/23/2023 12:00 AM ET)
Add
Compare
Today's Range
$18.70
$19.95
50-Day Range
$18.65
$29.09
52-Week Range
$13.05
$29.52
Volume
1.08 million shs
Average Volume
585,656 shs
Market Capitalization
$1.10 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.86

Replimune Group Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 7 Analyst Ratings

Consensus Analyst Price Target

$51.86
166.34% Upside
High Prediction$70.00
Average Prediction$51.86
Low Prediction$34.00
TypeCurrent
3/24/22 to 3/24/23
1 Month Ago
2/22/22 to 2/22/23
3 Months Ago
12/24/21 to 12/24/22
1 Year Ago
3/24/21 to 3/24/22
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
5 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$51.86$51.86$50.17$50.20
Predicted Upside166.34% Upside132.89% Upside143.03% Upside84.69% Upside
Get Replimune Group Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter.

REPL Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

REPL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Replimune Group Stock vs. The Competition

TypeReplimune GroupMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.64
2.47
Consensus RatingBuyBuyHold
Predicted Upside166.34% Upside1,923.97% Upside24.71% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/10/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$48.00 ➝ $50.00+98.41%
1/5/2023EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$60.00+128.57%
12/14/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$43.00 ➝ $58.00+119.78%
12/12/2022BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$40.00 ➝ $70.00+180.00%
12/7/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$30.00 ➝ $34.00+47.95%
5/24/2022Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$59.00 ➝ $52.00+265.68%
4/4/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$47.00 ➝ $39.00+108.44%
10/15/2021BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$60.00+101.68%
11/2/2020Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$67.00+60.25%
10/15/2020Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Peter Lawson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight$29.00 ➝ $50.00+37.93%
10/14/2020Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$30.00 ➝ $50.00+39.28%
10/14/2020Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Geulah Livshits
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy$30.00 ➝ $48.00+33.70%
(Data available from 3/24/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












REPL Price Target - Frequently Asked Questions

What is Replimune Group's consensus rating and price target?

According to the issued ratings of 7 analysts in the last year, the consensus rating for Replimune Group stock is Buy based on the current 7 buy ratings for REPL. The average twelve-month price prediction for Replimune Group is $51.86 with a high price target of $70.00 and a low price target of $34.00. Learn more on REPL's analyst rating history.

Do Wall Street analysts like Replimune Group more than its competitors?

Analysts like Replimune Group more than other Medical companies. The consensus rating score for Replimune Group is 3.00 while the average consensus rating score for medical companies is 2.64. Learn more on how REPL compares to other companies.

Does Replimune Group's stock price have much upside?

According to analysts, Replimune Group's stock has a predicted upside of 132.89% based on their 12-month price targets.

What analysts cover Replimune Group?

Replimune Group has been rated by EF Hutton Acquisition Co. I, and HC Wainwright in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:REPL) was last updated on 3/24/2023 by MarketBeat.com Staff